• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴黎地区 SARS-CoV-2 感染的高血清阳性率但短暂的免疫应答。

High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.

机构信息

Theravectys, Paris, France.

Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France.

出版信息

Eur J Immunol. 2021 Jan;51(1):180-190. doi: 10.1002/eji.202049058. Epub 2020 Dec 23.

DOI:10.1002/eji.202049058
PMID:33259646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7753614/
Abstract

Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high-throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 1847 participants working in three sites of an institution in Paris conurbation. In May-July 2020, 11% (95% confidence interval [CI]: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins, and 9.5% (95% CI: 8.2-11.0) were neutralizer in pseudo-typed virus assays. The prevalence of seroconversion was 11.6% (95% CI: 10.2-13.2) when considering positivity in at least one assay. In 5% of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4-8 weeks after the first sampling, anti-N and anti-S IgG titers and neutralization activity in pseudo-virus assay declined by 31%, 17%, and 53%, resulting thus in half-life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection.

摘要

尽管 COVID-19 大流行在 2020 年 3 月/4 月在法国达到高峰,但感染的流行率知之甚少。使用高通量方法,我们评估了来自巴黎都市区三个地点的一个机构的 1847 名参与者对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的血清学反应。在 2020 年 5 月至 7 月期间,11%(95%置信区间[CI]:9.7-12.6)的血清 IgG 对 SARS-CoV-2 的 N 和 S 蛋白呈阳性,9.5%(95%CI:8.2-11.0)在假型病毒测定中为中和抗体。当考虑至少一种测定呈阳性时,血清转化率为 11.6%(95%CI:10.2-13.2)。在 5%的 RT-qPCR 阳性个体中,未检测到系统性 IgG。在免疫个体中,21%的个体无症状。在 IgG 阳性个体中,52%出现嗅觉丧失(嗅觉丧失)和味觉丧失(味觉丧失),而在阴性个体中,这一比例为 3%。相比之下,30%的嗅觉丧失味觉丧失病例为血清阴性,这表明感染的真实流行率可能已达到 16.6%。在第一次采样后 4-8 周获得的血清中,抗-N 和抗-S IgG 滴度和假病毒测定中的中和活性分别下降了 31%、17%和 53%,半衰期分别为 35、87 和 28 天。所研究的人群代表了巴黎的活跃工作者。血清学系统反应的短寿命表明对真实感染流行率的低估。

相似文献

1
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.巴黎地区 SARS-CoV-2 感染的高血清阳性率但短暂的免疫应答。
Eur J Immunol. 2021 Jan;51(1):180-190. doi: 10.1002/eji.202049058. Epub 2020 Dec 23.
2
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.康复的 COVID-19 患者体内抗 SARS-CoV-2 抗体的特征。
Viruses. 2021 Apr 16;13(4):697. doi: 10.3390/v13040697.
3
Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.意大利东北部一个 COVID-19 病例高发地区 SARS-CoV-2 IgG 抗体的流行情况:一项基于人群的研究。
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7. doi: 10.1016/j.cmi.2020.11.013. Epub 2020 Nov 28.
4
Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.法国郊区人群中 SARS-CoV-2 血清流行率、症状谱和血清中和抗体情况
Viruses. 2021 Jun 4;13(6):1076. doi: 10.3390/v13061076.
5
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.比较分析来自人类血清样本的 SARS-CoV-2 结合抗体(IgG、IgM、IgA)和中和抗体。
J Immunol Methods. 2021 Feb;489:112937. doi: 10.1016/j.jim.2020.112937. Epub 2020 Nov 28.
6
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.评估针对 SARS-CoV-2 的 IgG 和中和抗体的免疫原性检测方法的稳健验证和性能比较。
PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022.
7
Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.血清学检测评估康复的新冠肺炎患者中高度可变的新冠病毒中和抗体活性。
J Clin Microbiol. 2020 Nov 18;58(12). doi: 10.1128/JCM.02005-20.
8
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.COVID-19 患者症状出现后七个月内 SARS-CoV-2 特异性和中和抗体的动力学。
Microbiol Spectr. 2021 Oct 31;9(2):e0059021. doi: 10.1128/Spectrum.00590-21. Epub 2021 Sep 22.
9
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.中国北京一家三级甲等医院中新冠病毒肺炎患者抗体反应的纵向分析
Front Immunol. 2021 Mar 15;12:614436. doi: 10.3389/fimmu.2021.614436. eCollection 2021.
10
SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.在犹太教堂社区爆发的 SARS-CoV-2:抗 SARS-CoV-2 IgG 反应的持久性和强度。
Epidemiol Infect. 2021 Jun 24;149:e153. doi: 10.1017/S0950268821001369.

引用本文的文献

1
Longitudinal analysis of passively and actively acquired SARS-CoV-2 antibodies in infants with repeat newborn screening samples.对具有重复新生儿筛查样本的婴儿中被动和主动获得的SARS-CoV-2抗体的纵向分析。
Sci Rep. 2025 Jul 4;15(1):23881. doi: 10.1038/s41598-025-09140-6.
2
Viruses of parasites: A roadmap toward diagnostic and therapeutic development.寄生虫病毒:诊断与治疗发展路线图。
PLoS Negl Trop Dis. 2025 Apr 10;19(4):e0012982. doi: 10.1371/journal.pntd.0012982. eCollection 2025 Apr.
3
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.一种表达融合前稳定的 SARS-CoV-2 刺突蛋白的麻疹载体候选疫苗已进入 I/II 期临床试验:在临床前小鼠模型中的候选物选择。
J Virol. 2024 May 14;98(5):e0169323. doi: 10.1128/jvi.01693-23. Epub 2024 Apr 2.
4
Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.味觉丧失是 COVID-19 的一个独特症状:系统评价和荟萃分析。
Chem Senses. 2023 Jan 1;48. doi: 10.1093/chemse/bjad043.
5
Application of Machine Learning Prediction of Individual SARS-CoV-2 Vaccination and Infection Status to the French Serosurveillance Survey From March 2020 to 2022: Cross-Sectional Study.应用机器学习预测个体 SARS-CoV-2 疫苗接种和感染状态在 2020 年 3 月至 2022 年法国血清学监测调查中的应用:横断面研究。
JMIR Public Health Surveill. 2023 Nov 28;9:e46898. doi: 10.2196/46898.
6
Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.2020 年 1 月至 12 月,在世界卫生组织欧洲区域广泛推出疫苗接种计划之前,对 SARS-CoV-2 抗体血清流行率进行系统评价,并对证据进行评估。
BMJ Open. 2023 Nov 6;13(11):e064240. doi: 10.1136/bmjopen-2022-064240.
7
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.法国癌症中心医护人员 SARS-CoV-2 感染血清阳性率和焦虑的一年随访:PRO-SERO-COV 研究。
Int J Environ Res Public Health. 2023 May 25;20(11):5949. doi: 10.3390/ijerph20115949.
8
Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome.抗原特异性抗体特征与 COVID-19 结局相关。
Viruses. 2023 Apr 20;15(4):1018. doi: 10.3390/v15041018.
9
Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2.在感染 SARS-CoV-2 的个体中,化学感觉缺陷是血清学反应的最佳预测指标。
PLoS One. 2022 Dec 14;17(12):e0274611. doi: 10.1371/journal.pone.0274611. eCollection 2022.
10
Seroprevalence of SARS-CoV-2 antibodies among Forcibly Displaced Myanmar Nationals in Cox's Bazar, Bangladesh 2020: a population-based cross-sectional study.2020 年孟加拉国考克斯巴扎尔地区被迫流离失所的缅甸国民中 SARS-CoV-2 抗体的血清流行率:一项基于人群的横断面研究。
BMJ Open. 2022 Nov 21;12(11):e066653. doi: 10.1136/bmjopen-2022-066653.

本文引用的文献

1
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study.俄罗斯圣彼得堡人群中 SARS-CoV-2 抗体的血清流行率:一项基于人群的研究。
Sci Rep. 2021 Jun 21;11(1):12930. doi: 10.1038/s41598-021-92206-y.
2
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.法国 SARS-CoV-2 抗体的流行率:全国血清学监测结果。
Nat Commun. 2021 May 21;12(1):3025. doi: 10.1038/s41467-021-23233-6.
3
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort.医院工作人员中未使用个人防护装备的高风险暴露与感染严重急性呼吸综合征冠状病毒2——CoV-CONTACT队列研究
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2021.01.026. Epub 2021 Feb 3.
4
SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.SARS-CoV-2 血清流行率趋势在 COVID-19 爆发期间在米兰的健康献血者中。
Blood Transfus. 2021 May;19(3):181-189. doi: 10.2450/2021.0324-20. Epub 2021 Feb 3.
5
Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study.用于鉴定 SARS-CoV-2 感染血清学特征的多重分析:基于抗体的诊断和机器学习研究。
Lancet Microbe. 2021 Feb;2(2):e60-e69. doi: 10.1016/S2666-5247(20)30197-X. Epub 2020 Dec 21.
6
IgA dominates the early neutralizing antibody response to SARS-CoV-2.IgA 在针对 SARS-CoV-2 的早期中和抗体反应中占主导地位。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.
7
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.针对 SARS-CoV-2 感染的强大中和抗体可长期存在。
Science. 2020 Dec 4;370(6521):1227-1230. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.
8
Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.新型冠状病毒肺炎患者和健康志愿者发病后 6 个月内抗 SARS-CoV-2 抗体的血清阳性率。
Eur J Immunol. 2020 Dec;50(12):2025-2040. doi: 10.1002/eji.202048970. Epub 2020 Nov 10.
9
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价:动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
10
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts.马萨诸塞州切尔西的 SARS-CoV-2 抗体高血清阳性率。
J Infect Dis. 2020 Nov 13;222(12):1955-1959. doi: 10.1093/infdis/jiaa579.